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Objectives. The purpose of this study was to investigate whether
atrial and brain natriuretic peptides (ANP and BNP, respectively)
represent autocrine/paracrine factors and are accumulated in
pericardial fluid.
Background. ANP and BNP, systemic hormones produced by
the heart, have elevated circulating levels in patients with heart
failure. Recent evidence suggests that the heart itself is one of the
target organs for these peptides.
Methods. With an immunoreactive radiometric assay, we mea-
sured the concentrations of these peptides in plasma and pericar-
dial fluid simultaneously in 28 patients during coronary artery
bypass graft surgery.
Results. The pericardial levels of BNP were markedly elevated
in patients with impaired left ventricular function. We investi-
gated the correlation of ANP and BNP levels in plasma or
pericardial fluid with left ventricular hemodynamic variables.
None of the hemodynamic variables correlated with ANP levels in
plasma or pericardial fluid. Both plasma and pericardial fluid
levels of BNP were significantly related to left ventricular end-
diastolic and systolic volume indexes (LVEDVI and LVESVI,
respectively). In addition, BNP pericardial fluid levels had closer
relations with LVEDVI (r 5 0.679, p < 0.0001) and LVESVI (r 5
0.686, p < 0.0001) than did BNP plasma levels (LVEDVI: r 5
0.567, p 5 0.0017; LVESVI: r 5 0.607, p 5 0.0010). BNP levels in
pericardial fluid but not in plasma correlated with left ventricular
end-diastolic pressure (r 5 0.495, p 5 0.0074).
Conclusions. BNP levels in pericardial fluid served as more
sensitive and accurate indicators of left ventricular dysfunction
than did BNP levels in plasma. Thus, BNP may be secreted from
the heart into the pericardial space in response to left ventricular
dysfunction, and it may have a pathophysiologic role in heart
failure as an autocrine/paracrine factor.
(J Am Coll Cardiol 1998;31:399–403)
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Atrial natriuretic peptide (ANP) and brain natriuretic peptide
(BNP) are members of a family of vasoactive substances that
are produced by the heart (1–5). The synthesis of these
peptides is augmented by the increased wall tension or stretch
of cardiac chambers (6,7). Once these peptides are released
from atrial or ventricular myocytes, most of them are believed
to go into the bloodstream. Circulating peptides serve to
unload the heart through their natriuretic, diuretic and vaso-
dilative properties (1–3). Earlier studies (4,7–10) reported that
plasma levels of ANP and BNP are elevated in patients with
various heart diseases including cardiomyopathy and ischemic
heart disease. These levels are roughly correlated with indica-
tors of left ventricular systolic and diastolic dysfunction. How-
ever, the plasma levels of ANP and BNP change greatly with
exercise, body position, anesthesia, surgical stress and minimal
volume overload, among other factors. There is no direct
evidence that their plasma levels provide accurate information
on the left ventricular function of patients with heart failure.
Apart from acting as systemic hormones, ANP and BNP
may have local actions at the site of their synthesis. Recent
studies (11) demonstrated that genes for natriuretic peptide
receptors are expressed in cardiac myocytes and fibroblasts and
that ANP and BNP stimulate cyclic guanosine monophosphate
(cGMP) accumulation in these cells. These findings support
the hypothesis that the heart itself is one of the target organs
for these peptides. In addition, natriuretic peptides are suffi-
cient to inhibit deoxyribonucleic acid (DNA) synthesis in
cardiac fibroblasts (12), suggesting their important paracrine
role in the structural remodeling of the heart by regulating
fibroblast growth. Thus, the local accumulation of these pep-
tides adjacent to the heart might have important pathophysi-
ologic significance. However, it is unknown whether 1) ANP
and BNP are diffusible, more concentrated in pericardial fluid
than in blood, and 2) their levels in pericardial fluid have
prognostic and therapeutic implications. Therefore, the
present study was designed to determine whether ANP and
BNP are concentrated in pericardial fluid and whether these
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concentrations relate to the left ventricular dysfunction in
patients with ischemic heart disease.
Methods
Patient profile. The 28 patients in this study underwent
coronary artery bypass graft surgery because of double- (n 5
12) or triple- (n 5 16) vessel disease. The mean age of the
patients (22 men and 6 women) was 66 6 7 years. All patients
were clinically evaluated before the operation by cardiac
catheterization. None showed signs of decompensated conges-
tive heart failure at the time of operation and cardiac cathe-
terization. All underwent biplane left ventriculography and
selective coronary angiography according to standard tech-
niques. The left ventricular end-diastolic and end-systolic
volume indexes (LVEDVI and LVESVI, respectively) and the
ejection fraction (EF) were calculated from left ventricular
cineangiograms performed in the right anterior oblique pro-
jection by the method of Kennedy et al. (13). The patients were
classified into two groups: group I, the 5 patients with normal
left ventricular function (i.e., EF $50% and left ventricular
end-diastolic pressure [LVEDP] #18 mm Hg), and group II,
the 23 patients with impaired left ventricular function (i.e.,
abnormal values for EF or LVEDP).
All patients gave written informed consent. The study
protocol was approved by the ethical committee on human
research of Takeda Hospital.
Sampling of plasma and pericardial fluid. Immediately
after the incision of the pericardium, undiluted samples of
pericardial fluid were obtained before heparinization. At the
same time, blood was withdrawn from the cannulated brachial
artery. These samples were collected in sterile tubes, placed
immediately on ice, clarified by centrifugation at 3,000 g for
10 min at 4°C and rapidly frozen at 280°C.
Measurement of plasma and pericardial fluid levels of ANP
and BNP by radioimmunoassay. BNP levels in plasma and
pericardial fluid were measured as previously described (4,7–
9). Briefly, [Tyr82]-human BNP [83-108] (1 mg) was radioiodi-
nated by the chloramine T method. The specific activity of
125I-labeled [Tyr82]-human BNP [83-108] ranged from 500 to
900 mCi/mg. The monoclonal antibody against human BNP (4)
(final dilution of ascites, 1:5 3 106) was incubated with either
standard human BNP or samples in 0.2-ml assay buffer (50
mmol/liter phosphate buffer, pH 7.4, containing 0.1% gelatin
[Merck, Darmstadt, Germany], 0.1% Triton X-100, 1 mmol/
liter Na2EDTA, 0.2 mmol/liter L-cystine and 0.1% NaN3) for
24 h at 4°C. Bound and free ligands were separated by adding
1.0 ml of a suspension of dextran-coated charcoal, consisting of
250 mg of Norit SX Plus (Norit Vereenging NV, The Nether-
lands) and 25 mg of Dextran T-70 (Pharmacia, Uppsala,
Sweden) in 100 ml of 50 mmol/liter phosphate buffer, pH 7.4,
containing 0.01% merthiolate.
The measurement of ANP levels in plasma and pericardial
fluid by radioimmunoassay was performed as reported previ-
ously (14).
Statistical analysis. Clinicopathologic data are expressed
as the mean value 6 SD. Statistical comparisons were per-
formed by chi-square analysis, Student t test, or one-way
analysis of variance with multiple comparisons, when appro-
priate. Significance was designated at the probability value of
p , 0.01. Linear regression analysis was used to assess the
relation between natriuretic peptide levels and hemodynamic
variables.
Results
Plasma and pericardial fluid levels of ANP and BNP.
Table 1 shows the clinical characteristics of patients in group I
and group II. No group I patient but 10 of the 23 group II
patients had an old myocardial infarction. EF was lower and
LVEDP, LVEDVI and LVESVI were higher in group II than
in group I. However, there were no differences in gender or
mean aortic pressure between the two groups. Figure 1 shows
plasma and pericardial fluid levels of ANP and BNP in the two
groups. In group I, plasma levels of BNP were lower than those
of ANP. In group II, plasma ANP and BNP levels were both
higher than plasma levels in group I, but BNP plasma levels
were higher than ANP levels. Thus, the plasma level ratio in
group II compared with group I was much higher in BNP
(group II/I 22-fold) than in ANP (group II/I 3.9-fold). ANP
and BNP levels were both higher in pericardial fluid than in
plasma. In contrast to plasma levels, pericardial fluid levels of
BNP were higher than those of ANP in both groups. Similar to
Abbreviations and Acronyms
ANP 5 atrial natriuretic peptide
BNP 5 brain natriuretic peptide
cGMP 5 cyclic guanosine monophosphate
DNA 5 deoxyribonucleic acid
EF 5 ejection fraction
LVEDP 5 left ventricular end-diastolic pressure
LVEDVI 5 left ventricular end-diastolic volume index
LVESVI 5 left ventricular end-systolic volume index
Table 1. Clinical Characteristics of Patients with Ischemic Heart
Disease, With Normal (group I) or Impaired (group II) Left
Ventricular Function
Group I
(n 5 5)
Group II
(n 5 23)
p
Value
Male/female 4/1 19/4 NS
History of MI 0/5 10/23 NS
EF (%) 57 6 4 43 6 9 , 0.005
LVEDP (mm Hg) 15 6 6 25 6 8 , 0.05
LVEDVI (ml/m2) 57 6 19 97 6 45 0.06
LVESVI (ml/m2) 24 6 10 53 6 40 0.06
Mean AoP (mm Hg) 104 6 16 103 6 16 NS
Data are presented as number of patients or mean value 6 SD. AoP 5 aortic
pressure; EF 5 ejection fraction; LVEDP 5 left ventricular end-diastolic
pressure; LVEDVI 5 left ventricular end-diastolic volume index; LVESVI 5 left
ventricular end-systolic volume index; MI 5 myocardial infarction.
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plasma levels, the pericardial fluid level ratio in group II
compared with group I was much higher for BNP (27-fold)
than for ANP (8.9-fold). Further, the elevation of ANP and
BNP levels in group II compared with group I was greater in
pericardial fluid than in plasma. Thus, BNP levels in the
pericardial fluid of group II patients were extremely high (Fig.
1).
Relations between natriuretic peptide levels in plasma or
pericardial fluid and indicators for left ventricular function.
Table 2 shows the correlations between hemodynamic vari-
ables and ANP or BNP levels in plasma or pericardial fluid. In
plasma, ANP levels correlated with none of the hemodynamic
variables, but BNP levels positively correlated with LVEDVI
(r 5 0.567, p 5 0.0017) and LVESVI (r 5 0.607, p 5 0.0010).
In pericardial fluid, ANP levels correlated with none of the
hemodynamic variables. Notably (Fig. 2), BNP levels had a
very close positive relation with LVESVI (r 5 0.686, p ,
0.0001) and LVEDVI (r 5 0.679, p , 0.0001) and a significant
relation with LVEDP (r 5 0.495, p 5 0.0074). None of these
peptides levels in plasma or pericardial fluid correlated with
age, heart rate or aortic pressure. In summary, 1) BNP had a
much closer relation with left ventricular hemodynamic vari-
ables than did ANP in both plasma and pericardial fluid; and
2) BNP had closer relations with these variables in pericardial
fluid than in plasma.
Effect of mitral regurgitation, hypertension and myocardial
ischemia on natriuretic peptide levels in plasma or pericardial
fluid. In group II, no patient had significant mitral regurgita-
tion greater than Seller’s grade II, as assessed by left ventricu-
lography performed during cardiac catheterization. Only one
patient had trivial mitral regurgitation (Seller’s grade I).
However, this patient had normal left atrial dimension. In
addition, the hemodynamic variables and the ANP and BNP
levels in plasma and pericardial fluid of this patient were within
a range of the variation in group II. Therefore, the effect of
mitral regurgitation on peptide levels in group II may be
minimal, if any.
Group II contained nine patients with significant hyperten-
sion (.160/95 mm Hg) at the time of cardiac catheterization.
However, these patients showed no evidence of left ventricular
hypertrophy by echocardiography. Their ANP and BNP levels
in plasma and pericardial fluid and hemodynamic variables
including left ventricular EF, LVEDP, LVEDVI and LVESVI
did not differ from those without hypertension. Therefore, the
effect of this factor on peptide levels may be minimal, if any.
We further classified the patients into the following four
ischemic groups: stable angina (n 5 7), unstable angina (n 5
7), recent myocardial infarction (n 5 4, within 3 months from
the onset of infarction) and old myocardial infarction (n 5 10).
No patient was status post acute myocardial infarction (within
3 days from the onset of infarction). Hemodynamic variables
and the ANP and BNP levels of each patient group are shown
in Table 3. There were no significant differences in hemody-
namic variables and peptide levels between the groups with
stable and unstable angina or between the groups with old and
recent myocardial infarction.
Figure 1. ANP and BNP levels in the plasma and pericardial fluid of
patients with ischemic heart disease with normal (group I, n 5 5) or
impaired (group II, n 5 23) left ventricular function.
Table 2. Regression Analyses of Association Between Hemodynamic Variables and Plasma or Pericardial Fluid Levels of Atrial and Brain
Natriuretic Peptides
ANP in Plasma BNP in Plasma ANP in Pericardial Fluid BNP in Pericardial Fluid
Coefficient p Value Coefficient p Value Coefficient p Value Coefficient p Value
Patient age (yr) r 5 0.319 0.0984 r 5 0.113 0.5660 r 5 0.299 0.1221 r 5 0.101 0.6090
Heart rate (beats/min) r 5 0.152 0.4480 r 5 0.323 0.1006 r 5 0.252 0.2055 r 5 0.310 0.1152
Mean AoP (mm Hg) r 5 0.120 0.9539 r 5 0.092 0.6693 r 5 0.163 0.4475 r 5 0.122 0.5685
LVEDP (mm Hg) r 5 0.150 0.4453 r 5 0.395 0.0375 r 5 0.245 0.2085 r 5 0.495 0.0074
LVEDVI (ml/m2) r 5 0.236 0.2267 r 5 0.567 0.0017 r 5 0.367 0.0550 r 5 0.679 , 0.0001
LVESVI (ml/m2) r 5 0.310 0.1231 r 5 0.607 0.0010 r 5 0.417 0.0343 r 5 0.686 , 0.0001
EF (%) 2r 5 0.238 0.2220 2r 5 0.372 0.0513 2r 5 0.318 0.0988 2r 5 0.411 0.0300
ANP 5 atrial natriuretic peptide; BNP 5 brain natriuretic peptide; other abbreviations as in Table 1.
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Discussion
Significance of ANP and BNP in left ventricular dysfunc-
tion. ANP and BNP are heart-derived peptides that are
activated by the increased wall tension or stretch of cardiac
chambers (1–7). Earlier studies (4,7–10) reported elevated
plasma levels of ANP and BNP in association with left
ventricular dysfunction. However, because the plasma levels of
these peptides vary greatly from time to time in response to
various minimal stresses, it is unknown whether they provide
accurate information on the disease status and prognosis of
patients with ischemic heart disease. In addition, as recent
studies suggest that the heart itself is one of the target organs
for natriuretic peptides, it is important to establish whether
ANP and BNP are accumulated in the pericardial space. Our
present results revealed that the levels of ANP and BNP were
higher in pericardial fluid than in plasma, and that BNP levels
in pericardial fluid had closer relations with indicators of left
ventricular dysfunction than did BNP levels in plasma.
In healthy persons, the plasma concentration of BNP has
been reported to be lower than that of ANP (4,7–9). Con-
versely, in chronic heart failure, the plasma BNP/ANP ratio is
reversed. Furthermore, BNP levels increase more rapidly than
ANP levels in the acute phase of myocardial infarction (8) and
in obstructive form of hypertrophic cardiomyopathy (9). Com-
patible with these findings, the present study demonstrated
that both plasma and pericardial fluid levels of BNP increased
more markedly in association with left ventricular dysfunction
than did those of ANP. BNP is secreted predominantly from
the ventricle in response to ventricular wall stress and stretch
(4,7–9). In contrast, the atria provide main source of plasma
ANP (1,2), although increased amounts of ANP are secreted
from the ventricle in patients with heart failure (4,7). Circu-
Figure 2. Correlations between pericar-
dial fluid BNP levels and EF, LVEDP
and LVEDVI or LVESVI in patients
with normal (group I, solid circles) or
impaired (group II, open circles) left
ventricular function.
Table 3. Influence of Myocardial Ischemia on Atrial and Brain Natriuretic Peptide Levels in Plasma
or Pericardial Fluid*
Angina Pectoris Myocardial Infarction
Stable
(n 5 7)
Unstable
(n 5 7)
Recent
(n 5 4)
Old
(n 5 10)
Plasma ANP (pg/ml) 9 6 2 6 6 1 89 6 84 11 6 4
Plasma BNP (pg/ml) 5 6 0 18 6 6 261 6 236 94 6 41
Pericardial fluid ANP (pg/ml) 15 6 6 15 6 4 177 6 168 83 6 41
Pericardial fluid BNP (pg/ml) 144 6 73 308 6 92 1,720 6 1,370 1,682 6 663
EF (%) 55 6 2 48 6 3 41 6 4 38 6 3
LVEDP (mm Hg) 18 6 1 23 6 4 26 6 4 25 6 3
LVEDVI (ml/m2) 65 6 7 75 6 11 104 6 16 112 6 18
LVESVI (ml/m2) 29 6 4 33 6 9 66 6 17 71 6 15
*There were no significant differences between patients with stable versus unstable angina or between patients with
recent or old myocardial infarction for any of the variables listed. Data are expressed as mean value 6 SD. Abbreviations
as in Tables 1 and 2.
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lating ANP and BNP are cleared through the clearance
(C)-receptor (15–17) expressed in a wide variety of tissues.
BNP has a lower affinity to the C-receptors than does ANP,
and thus has a longer half-life than that of ANP (18). Thus, the
sites of secretion and half-life may, at least in part, account for
the differences in plasma and pericardial fluid levels between
ANP and BNP.
Pericardial fluid BNP levels. The present results showed
higher levels of ANP and BNP in pericardial fluid than in
plasma. In the patients with normal left ventricular function,
plasma levels of BNP were lower than those of ANP, but this
relation was reversed in pericardial fluid. The higher levels of
these peptides (especially BNP) in pericardial fluid than in
plasma suggest that BNP is secreted more predominantly into
the pericardial space rather than into the bloodstream, or that
BNP has a longer half-life in the pericardial fluid than in
plasma. Our study also showed that pericardial fluid BNP
levels had closer relations with the indicators of left ventricular
dysfunction than did plasma BNP levels. Because natriuretic
peptides in plasma have relatively short half-lives, their plasma
levels are rapidly and greatly changed by anesthesia or surgical
stress. These findings indicate that pericardial fluid BNP levels
provide more sensitive, stable and accurate information than
do plasma BNP levels on left ventricular dysfunction due to
ischemic heart disease.
Relations between ANP and BNP levels and left ventricular
function. We defined group II patients as having impaired left
ventricular function. However, it is possible that some of these
patients have significant systolic dysfunction without diastolic
dysfunction, some have both systolic and diastolic dysfunction
and some have normal systolic but abnormal diastolic function.
In addition, the secretion of ANP and BNP from the heart is
accelerated by various stimuli, including catecholamines, en-
dothelin and angiotensin II, among others. The levels of these
endocrine factors as well as the mechanism causing congestive
heart failure may vary in each patient. Thus, these factors may
account for the variability seen in Figure 2. Further studies in
a larger number of patients are needed to clarify the contri-
bution of each factor to the levels of ANP and BNP in plasma
and pericardial fluid.
Roles of pericardial fluid ANP and BNP. What are the
pathophysiologic roles of ANP and BNP in pericardial fluid in
patients with left ventricular dysfunction? Several lines of
evidence support the idea that the heart itself is a site of action
of ANP and BNP. 1) The physiologic function of isolated
cardiac myocytes is altered by the administration of ANP
(19,20). 2) The genes for all three natriuretic peptide receptor
subtypes are expressed in the rat heart (11). 3) Both ANP and
BNP stimulate cGMP generation in purified cardiac myocytes
and in cardiac fibroblasts (11). 4) Both ANP and BNP inhibit
DNA synthesis in cardiac fibroblasts (12). These results, taken
together with the present findings indicating the accumulation
of natriuretic peptides in the pericardial space, suggest that
these peptides have a pathophysiologic role in heart failure as
autocrine/paracrine factors. The upregulation of cGMP in
cardiac myocytes and fibroblasts by ANP and BNP implies that
these peptides inhibit the remodeling of the heart by regulating
the growth of these cells. The reduction of cytosolic Ca21 by
ANP suggests that natriuretic peptides may have negative
inotropic action. Further study is necessary to determine
whether ANP and BNP have beneficial or harmful roles, as
autocrine/paracrine factors, in patients with left ventricular
dysfunction.
References
1. de Bold AJ, Borenstein HB, Veress AT, Sonenberg H. A rapid and potent
natriuretic response to intravenous injection of atrial myocardial extract in
rats. Life Sci 1981;28:89–94.
2. Brenner BM, Ballermann BJ, Gunning ME, Zeidel ML. Diverse biological
action of atrial natriuretic peptide. Physiol Rev 1990;70:665–99.
3. Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in
porcine brain. Nature 1988;332:78–81.
4. Mukoyama M, Nakao K, Hosoda K, et al. Brain natriuretic peptide as a
novel cardiac hormone in humans: evidence for an exquisite dual natriuretic
peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin
Invest 1991;87:1402–12.
5. Hasegawa K, Fujiwara H, Itoh H, et al. Light and electron microscopic
localization of brain natriuretic peptide in relation to atrial natriuretic
peptide in porcine atrium: immunohistochemical study using specific mono-
clonal antibodies. Circulation 1991;84:1203–9.
6. Edwards BS, Zimmerman RS, Schwab TR, Heublein DM, Burnett JC. Atrial
stretch, not pressure, is the principal determinant controlling the acute
release of atrial natriuretic peptide. Circulation 1988;62:191–5.
7. Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of
secretion of B-type natriuretic peptide in comparison with those of A-type
natriuretic peptide in normal subjects and patients with heart failure.
Circulation 1994;90:195–203.
8. Morita E, Yasue H, Yoshimura M, et al. Increased plasma levels of brain
natriuretic peptide in patients with acute myocardial infarction. Circulation
1993;88:82–91.
9. Hasegawa K, Fujiwara H, Doyama K, et al. Ventricular expression of brain
natriuretic peptide in hypertrophic cardiomyopathy. Circulation 1993;88:
372–80.
10. Omland T, Aakvaag A, Bonarjee VVS, et al. Plasma brain natriuretic
peptide as an indicator of left ventricular systolic function and long-term
survival after acute myocardial infarction: comparison with plasma atrial
natriuretic peptide and n-terminal proatrial natriuretic peptide. Circulation
1996;93:1963–9.
11. Xiongbin L, Jorg H, Frauke H, Richard S, Rudolf EL. Gene expression of
natriuretic peptide receptors in myocardial cells. Circ Res 1995;77:750–8.
12. Li C, David GG. Natriuretic peptides inhibit DNA synthesis in cardiac
fibroblasts. Hypertension 1995;25:227–34.
13. Kennedy JW, Trenholme SE, Kasser IS. Left ventricular volume and mass
from single plane angiogram: a comparison of anteroposterior and right
anterior oblique methods. Am Heart J 1970;80:343–52.
14. Nakao K, Sugawara A, Morii N, et al. Radioimmunoassay for alpha-human
and rat natriuretic polypeptide. Biochem Biophys Res Commun 1984;124:
815–21.
15. Fuller F, Porter JG, Arfsten AE, et al. Atrial natriuretic peptide clearance
receptor. J Biol Chem 1988;263:9395–401.
16. Porter JG, Arfsten AE, Fuller F, Miller JA, Gregory LC, Lewicki JA.
Isolation and function expression of the human atrial natriuretic peptide
clearance receptor cDNA. Biochem Biophys Res Commun 1990;171:796–
803.
17. Lowe DG, Camerato TR, Goeddel DV. cDNA sequence of human atrial
natriuretic peptide clearance receptor. Nucleic Acids Res 1990;18:3412.
18. Maack T. Receptors of atrial natriuretic factor. Annu Rev Physiol 1992;54:
11–27.
19. Neyses L, Vetter H. Action of atrial natriuretic peptide and angiotensin II on
the myocardium: studies in isolated rat ventricular cardiomyocytes. Biochem
Biophys Res Commun 1989;163:1435–43.
20. Tei M, Horie M, Makita T, et al. Atrial natriuretic peptide reduces the basal
level of cytosolic free Ca21 in guinea pig cardiac myocytes. Biochem Biophys
Res Commun 1990;167:413–8.
403JACC Vol. 31, No. 2 TANAKA ET AL.
February 1998:399–403 BNP IN PERICARDIAL FLUID
